VXRT trades 325.6% below Wall Street's consensus target of $2.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes VXRT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Vaxart, Inc. (VXRT) has a Wall Street consensus price target of $2.00, based on estimates from 3 covering analysts. With the stock currently trading at $0.47, this represents a potential upside of +325.6%. The company has a market capitalization of $114M.
Analyst price targets range from a low of $2.00 to a high of $2.00, representing a 0% spread in expectations. The median target of $2.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, VXRT trades at a trailing P/E of 6.7x. Analysts expect EPS to grow -213.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1.25, with bear and bull scenarios of $0.79 and $1.65 respectively. Model confidence stands at 42/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVAXNovavax, Inc. | $1.7B | $10.55 | $18.00 | +70.6% | Buy | — | 23 |
 IBRXImmunityBio, Inc. | $9.0B | $8.63 | $12.00 | +39.0% | Buy | — | 5 |
 CODXCo-Diagnostics, Inc. | $1M | $1.10 | $6.00 | +445.5% | Hold | — | 5 |
 OCGNOcugen, Inc. | $339M | $1.00 | $5.00 | +400.0% | Buy | — | 6 |
 DYAIDyadic International, Inc. | $15M | $0.41 | — | — | — | — | — |
 MRNAModerna, Inc. | $72.3B | $182.11 | $115.70 | -36.5% | Hold | — | 29 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
 SNYSanofi | $100.0B | $41.66 | $49.50 | +18.8% | Hold | 10.0x | 27 |
 GSKGSK plc | $99.6B | $49.71 | $60.00 | +20.7% | Hold | 13.8x | 29 |
 MRKMerck & Co., Inc. | $365.8B | $148.11 | $158.12 | +6.8% | Buy | 53.9x | 38 |
Quick answers to the most common questions about buying VXRT stock.
The consensus Wall Street price target for VXRT is $2, representing 325.6% upside from the current price of $0.4699. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
VXRT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $2 implies 325.6% upside from current levels.
VXRT's current price is $0.4699 with a consensus target of $2 (325.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $2 for VXRT, while the most conservative target is $2. The consensus of $2 represents the median expectation. Our quantitative valuation model projects a bull case target of $2 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
VXRT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month VXRT stock forecast based on 3 Wall Street analysts shows a consensus price target of $2, with estimates ranging from $2 (bear case) to $2 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1, with bear/bull scenarios of $1/$2.
Our quantitative valuation model calculates VXRT's fair value at $1 (base case), with a bear case of $1 and bull case of $2. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.
Wall Street analysts are very optimistic on VXRT, with a "Buy" consensus rating and $2 price target (325.6% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
VXRT analyst price targets range from $2 to $2, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2 consensus represents the middle ground. Our model's $1-$2 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.